BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 33760860)

  • 1. Polymorphisms of T- cell leukemia 1A gene loci are not related to the development of adjuvant letrozole-induced adverse events in breast cancer.
    Umamaheswaran G; Kadambari D; Muthuvel SK; Kumar NAN; Dubashi B; Aibor Dkhar S; Adithan C
    PLoS One; 2021; 16(3):e0247989. PubMed ID: 33760860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.
    Umamaheswaran G; Kadambari D; Muthuvel SK; Kalaivani S; Devi J; Damodaran SE; Pradhan SC; Dubashi B; Dkhar SA; Adithan C
    Breast Cancer Res Treat; 2020 Jul; 182(1):147-158. PubMed ID: 32385792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
    Ingle JN; Schaid DJ; Goss PE; Liu M; Mushiroda T; Chapman JA; Kubo M; Jenkins GD; Batzler A; Shepherd L; Pater J; Wang L; Ellis MJ; Stearns V; Rohrer DC; Goetz MP; Pritchard KI; Flockhart DA; Nakamura Y; Weinshilboum RM
    J Clin Oncol; 2010 Nov; 28(31):4674-82. PubMed ID: 20876420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.
    Leyland-Jones B; Gray KP; Abramovitz M; Bouzyk M; Young B; Long B; Kammler R; Dell'Orto P; Biasi MO; Thürlimann B; Harvey V; Neven P; Arnould L; Maibach R; Price KN; Coates AS; Goldhirsch A; Gelber RD; Pagani O; Viale G; Rae JM; Regan MM;
    Breast Cancer Res Treat; 2015 Dec; 154(3):543-55. PubMed ID: 26590813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphic genetic variations of cytochrome P450 19A1 and T-cell leukemia 1A genes in the Tamil population.
    Umamaheswaran G; Kadambari D; Kumar AS; Revathy M; Anjana R; Adithan C; Dkhar SA
    Environ Toxicol Pharmacol; 2015 Jan; 39(1):102-13. PubMed ID: 25481307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
    Leyland-Jones B; Gray KP; Abramovitz M; Bouzyk M; Young B; Long B; Kammler R; Dell'Orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Harvey VJ; Neven P; Treilleux I; Rasmussen BB; Maibach R; Price KN; Coates AS; Goldhirsch A; Pagani O; Viale G; Rae JM; Regan MM
    Breast Cancer Res Treat; 2015 Jun; 151(2):373-84. PubMed ID: 25935582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial.
    Fontein DB; Houtsma D; Nortier JW; Baak-Pablo RF; Kranenbarg EM; van der Straaten TR; Putter H; Seynaeve C; Gelderblom H; van de Velde CJ; Guchelaar HJ
    Breast Cancer Res Treat; 2014 Apr; 144(3):599-606. PubMed ID: 24590773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype, allele and haplotype frequencies of four TCL1A gene polymorphisms associated with musculoskeletal toxicity in the South Indian descent.
    Umamaheswaran G; Dkhar SA; Kumar AS; Srinivasa RK; Kadambari D; Adithan C
    Bioimpacts; 2014; 4(2):95-100. PubMed ID: 25035853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer.
    Wang J; Lu K; Song Y; Xie L; Zhao S; Wang Y; Sun W; Liu L; Zhao H; Tang D; Ma W; Pan B; Xuan Q; Liu H; Zhang Q
    PLoS One; 2013; 8(7):e68798. PubMed ID: 23894347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.
    Nabieva N; Fehm T; Häberle L; de Waal J; Rezai M; Baier B; Baake G; Kolberg HC; Guggenberger M; Warm M; Harbeck N; Wuerstlein R; Deuker JU; Dall P; Richter B; Wachsmann G; Brucker C; Siebers JW; Popovic M; Kuhn T; Wolf C; Vollert HW; Breitbach GP; Janni W; Landthaler R; Kohls A; Rezek D; Noesselt T; Fischer G; Henschen S; Praetz T; Heyl V; Kühn T; Krauss T; Thomssen C; Hohn A; Tesch H; Mundhenke C; Hein A; Hack CC; Schmidt K; Belleville E; Brucker SY; Kümmel S; Beckmann MW; Wallwiener D; Hadji P; Fasching PA
    Eur J Cancer; 2018 Jun; 96():82-90. PubMed ID: 29679775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
    Borrie AE; Rose FA; Choi YH; Perera FE; Read N; Sexton T; Lock M; Vandenberg TA; Hahn K; Younus J; Logan D; Potvin K; Yaremko B; Yu E; Lenehan J; Welch S; Teft WA; Kim RB
    Breast Cancer Res Treat; 2020 Sep; 183(2):365-372. PubMed ID: 32632513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
    Oesterreich S; Henry NL; Kidwell KM; Van Poznak CH; Skaar TC; Dantzer J; Li L; Hangartner TN; Peacock M; Nguyen AT; Rae JM; Desta Z; Philips S; Storniolo AM; Stearns V; Hayes DF; Flockhart DA
    Breast Cancer Res Treat; 2015 Nov; 154(2):263-73. PubMed ID: 26536870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients.
    Wang J; Lu K; Song Y; Zhao S; Ma W; Xuan Q; Tang D; Zhao H; Liu L; Zhang Q
    PLoS One; 2015; 10(7):e0133964. PubMed ID: 26218592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression.
    Liu M; Wang L; Bongartz T; Hawse JR; Markovic SN; Schaid DJ; Mushiroda T; Kubo M; Nakamura Y; Kamatani N; Goss PE; Ingle JN; Weinshilboum RM
    Breast Cancer Res; 2012 Mar; 14(2):R41. PubMed ID: 22405131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials.
    Conte B; Boni L; Bisagni G; Durando A; Sanna G; Gori S; Garrone O; Tamberi S; De Placido S; Schettini F; Pazzola A; Ponzone R; Montemurro F; Lunardi G; Notaro R; De Angioletti M; Turletti A; Mansutti M; Puglisi F; Frassoldati A; Porpiglia M; Fabi A; Generali D; Scognamiglio G; Rossi M; Brasó-Maristany F; Prat A; Cardinali B; Piccioli P; Serra M; Lastraioli S; Bighin C; Poggio F; Lambertini M; Del Mastro L
    Clin Cancer Res; 2023 Dec; 29(24):5217-5226. PubMed ID: 37888299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms.
    Hertz DL; Douglas JA; Miller RM; Kidwell KM; Gersch CL; Desta Z; Storniolo AM; Stearns V; Skaar TC; Hayes DF; Henry NL; Rae JM
    Support Care Cancer; 2022 Oct; 30(10):8059-8067. PubMed ID: 35776183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.
    Artigalás O; Vanni T; Hutz MH; Ashton-Prolla P; Schwartz IV
    BMC Med; 2015 Jun; 13():139. PubMed ID: 26067721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer.
    Park IH; Lee YS; Lee KS; Kim SY; Hong SH; Jeong J; Lee H; Ro J; Nam BH
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1263-71. PubMed ID: 21442439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of
    Dempsey JM; Kidwell KM; Gersch CL; Pesch AM; Desta Z; Storniolo AM; Stearns V; Skaar TC; Hayes DF; Henry NL; Rae JM; Hertz DL
    Pharmacogenomics; 2019 Jun; 20(8):571-580. PubMed ID: 31190621
    [No Abstract]   [Full Text] [Related]  

  • 20. Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.
    Kamdem LK; Xi J; Clark BL; Gregory BJ; Kidwell KM; Storniolo AM; Stearns V; Hayes DF; Gersch CL; Rae JM; Henry NL; Hertz DL
    Breast Cancer Res Treat; 2019 Jun; 175(2):297-303. PubMed ID: 30747308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.